



**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY. DOCKET NO.

10271-072-999

APPLICATION NO.

10/628,088

APPLICANT

Young et al.

FILING DATE

July 25, 2003

ART UNIT

1648

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR

**FOREIGN PATENT DOCUMENTS**

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
MH	B28	WO 91/16074	10/31/91	MedImmune, Inc.		
MH	B29	WO 02/43660	06/06/02	MedImmune, Inc.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T

EXAMINER

/Michelle Horning/

DATE CONSIDERED

10/04/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYJD-1636022v1

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	ATTY. DOCKET NO. <b>10271-072-999</b>	APPLICATION NO. <b>10/628,088</b>
	APPLICANT <b>Young et al.</b>	
	FILING DATE <b>July 25, 2003</b>	ART UNIT <b>1648</b>



**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR


**FOREIGN PATENT DOCUMENTS**

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
MH	B28	WO 91/16074	10/31/91	MedImmune, Inc.		
MH	B29	WO 02/43660	06/06/02	MedImmune, Inc.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T

<b>EXAMINER</b> /Michelle Horning/	<b>DATE CONSIDERED</b> 10/04/2006
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Express Mail Nos: EV 531 696 341 US  
EV 531 696 307 US**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)ATTY DOCKET NO.  
10271-072-999APPLICATION NO  
10/628,088APPLICANT  
*Young et al.*FILING DATE  
July 25, 2003GROUP  
1641**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
MH	A01	US 2002-0164326	11/7/02	Young			
	A02	US 2002-0102257	8/1/02	Johnson			
	A03	US 2002-0098189	7/25/02	Young			
	A04	US 2002-0051787	5/2/02	Prince			
	A05	US 2002-0018780	2/14/02	Koenig			
	A06	US 2002-0004046	1/10/02	Johnson			
	A07	2002 0001 798	1/3/02	Brams et al.			
	A08	US 2001-0034062	10/25/01	Koenig			
	A09	US 2001-0026798	10/4/01	Koenig			
	A10	4,526,938	7/2/85	Churchill et al.			
	A11	4,880,078	11/14/89	Inoue et al.			
	A12	5,166,057	11/24/92	Palese et al.			
	A13	5,128,326	7/7/92	Balazs et al.			
	A14	5,290,540	3/1/94	Prince et al.			
	A15	5,585,089	12/17/96	Queen et al.			
	A16	5,679,377	10/21/97	Bernstein et al.			
	A17	5,693,762	12/2/97	Queen et al.			
	A18	5,811,524	0/22/98	Brams et al.			
	A19	5,824,307	10/20/98	Johnson			
	A20	5,840,298	11/24/98	Brams et al.			
	A21	5,854,037	12/29/98	Palese et al.			
	A22	5,855,913	1/5/99	Hanes et al.			
	A23	5,866,125	2/2/99	Brams et al.			
	A24	5,874,064	2/23/99	Edwards et al.			

MH	A25	5,912,015	6/15/99	Bernstein et al.			
	A26	5,916,597	6/29/99	Lee et al.			
	A27	5,934,272	8/10/99	Lloyd et al.			
	A28	5,939,068	8/17/99	Brams et al.			
	A29	5,955,364	9/21/99	Brams et al.			
	A33	5,958,765	9/28/99	Brams et al.			
	A34	5,985,309	11/16/99	Edwards et al.			
	A35	5,985,320	11/16/99	Edwards et al.			
	A36	5,989,463	11/23/99	Tracy et al.			
	A37	6,019,968	2/1/00	Platz et al.			
	A38	6,096,551	8/1/00	Barbas et al.			
	A39	6,146,642	11/14/00	Garcia-Sastre et al.			
↓	A40	6,537,809	3/25/03	Brams			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
MH	B01	EP 0 702 085 A1	2/20/96	EPO				
	B02	EP 0 780 475 A1	6/25/97	EPO				
	B03	PCT/NL02/00040	1/18/02	PCT				
	B04	WO 91/05548	5/2/91	PCT				
	B05	WO 92/19244	11/12/92	PCT				
	B06	WO 96/05229	2/22/96	PCT				
	B07	WO 96/20698	7/11/96	PCT				
	B08	WO 96/34625	11/7/96	PCT				
	B09	WO 97/06270	2/20/97	PCT				
	B10	WO 97/12032	4/3/97	PCT				
	B11	WO 97/32572	9/12/97	PCT				
	B12	WO 97/34631	9/25/97	PCT				
	B13	WO 97/44013	11/27/97	PCT				
	B14	WO 98/02530	1/22/98	PCT				
	B15	WO 98/13501	4/2/98	PCT				
	B16	WO 98/31346	7/23/98	PCT				
	B17	WO 98/53078	11/26/98	PCT				
	B18	WO 99/02657	1/21/99	PCT				
	B19	WO 99/15672	4/1/99	PCT				
	B20	WO 99/15154	4/1/99	PCT				
	B21	WO 99/20253	4/29/99	PCT				
	B22	WO 99/66903	12/29/99	PCT				
	B23	WO 00/20600	4/13/00	PCT				
↓	B24	WO 00/29584	5/25/00	PCT				

MH	B25	WO 01/64751	9/7/01	PCT				
	B26	WO 02/057302	7/25/02	PCT				
	B27	FR 2758331	1/14/97	France				

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

	C01	Abman et al., 1988, "Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis," J. Pediatr. 113(5):826-830
	C02	Ahmadian et al., 1999, "Detection and characterization of proteins encoded by the second ORF of the M2 gene of pneumoviruses," J. Gen. Virol. 80(Pt. 8):2011-2016
	C03	American Academy of Pediatrics Committee on Infectious Diseases, 1993, "Use of Ribavirin in the Treatment of Respiratory Syncytial Virus Infection," Pediatrics 92(3):501-504
	C04	Anderson et al., 1985, "Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay," J. Clin. Microbiol. 22:1050-1052
	C05	Bayon-Auboyer et al., 1999, "Comparison of F-, G- and N-based RT-PCR protocols with conventional virological procedures for the detection and typing of turkey rhinotracheitis virus," Arch. Virol. 144(6):1091-1109
	C06	Bayon-Auboyer et al., 2000, "Nucleotide sequences of the F, L and G protein genes of two non-A/non-B avian pneumoviruses (APV) reveal a novel APV subgroup," J. Gen. Virol. 81(Pt 11):2723-2733
	C07	Beare et al., 1975, "Trials in man with live recombinants made from A/PR/8/34 (H0 N1) and wild H3 N2 influenza viruses," Lancet 2(7938):729-732
	C08	Beeler et al., "Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function," J. Virol. 63(7):2941-2950
	C09	Bentley et al., 1980, "Human immunoglobulin variable region genes - DNA sequences of two V kappa genes and a pseudogene," Nature 288(5792):730-733
	C10	Botts et al., 1984, "On the mechanism of energy transduction in myosin subfragment 1," Proc. Natl. Acad. Sci. USA 81(7):2060-2064
	C11	Boulianne et al., 1984, "Production of functional chimaeric mouse/human antibody," Nature 312(5995):643-646
	C12	Bridgen et al., 1996, "Rescue of a segmented negative-strand RNA virus entirely from cloned complementary DNAs," Proc. Natl. Acad. Sci. USA 93(26):15400-15404
	C13	Buchholz et al., 1999, "Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter," J. Virol. 73(1):251-259
	C14	Buys et al., 1980, "A preliminary report on the isolation of a virus causing sinusitis in turkeys in South Africa and attempts to attenuate the virus," Turkey 28:36-46
	C15	Carson et al., 1986, "Human lymphocyte hybridomas and monoclonal antibodies," Adv. Immunol. 38:275-311
	C16	Cavanagh et al., 1988, "Pneumovirus-like characteristics of the mRNA and proteins of turkey rhinotracheitis virus," Virus Res. 11(3):241-256
	C17	Cleek et al., 1997, "Biodegradable Polymeric Carriers for a bFGF Antibody for Cardiovascular Application," Pro. Int'l. Symp. Control. Rev. Bioact. Mater. 24:853-854
	C18	Collins et al., 1988, "Characterization of a virus associated with turkey rhinotracheitis," J. Gen. Virol. 69(Pt 4):909-916
	C19	Collins et al., 1995, "Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development," Proc. Natl. Acad. Sci. USA 92(25):11563-11567
	C20	Collins et al., 1993, Avian Pathology, 22:469-479
	C21	Conrad et al., 1987, "Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic," Pediatr. Infect. Dis. J. 6(2):152-158
	C22	Cook et al., 1988, Avian Pathol. 17:403-410
	C23	Cook et al., 1993, Avian Pathology 22:257-273
	C24	Cruse et al., 1995, Illustrated Dictionary of Immunology, Boca Raton: CRC Press, pp. 18-19
	C25	Domachowske et al., 1999, "Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment," Clin. Microbiol. Rev. 12(2):298-309
	C26	Dorland's Illustrated Medical Dictionary, 1994, 28 <sup>th</sup> ed., Philadelphia: WB Saunders pp. 874
↓	C27	Duenas et al., 1996, "In vitro immunization of naïve human B cells yields high affinity immunoglobulin G antibodies as illustrated by phage display," Immunology 89:1-7

MH	C28	Duenas et al., 1996, "Selection of phage displayed antibodies based on kinetic constants," Mol. Immunol. 33(3):279-285
	C29	Durbin et al., 2000, "Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy," J. Virol. 74(15):6821-6831
	C30	Durbin et al., 1997, "Recovery of infectious human parainfluenza virus type 3 from cDNA," Virology 235(2):323-332
	C31	Ennis et al., 1976, "Recombination of influenza A virus strains: effect on pathogenicity," Dev. Biol. Stand. 33:220-225
	C32	Evans, ed., 1989, Viral infections of Humans, Epidemiology and Control. 3rd ed., pp. 22-28, and 525-544 Plenum Publishing Corp. New York
	C33	Everitt et al., 1996, "The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers," J. Infect. Dis. 174(3):463-469
	C34	Falsey, 1991, "Noninfluenza respiratory virus infection in long-term care facilities," Infect. Control Hosp. Epidemiol. 12(10):602-608
	C35	Feigen et al., 1987, Textbook of Pediatric Infectious Diseases, WB Saunders, Philadelphia, pp. 1653-1675
	C36	Fields et al., eds, 1990, Fields Virology, 2 <sup>nd</sup> ed., Raven Press, New York 1:1045-1072
	C37	Flint et al., 2000, Principles of virology, Molecular Biology, Pathogenesis and Control. ASM Press pp. 25-56
	C38	Florent et al., 1977, "RNAs of influenza virus recombinants derived from parents of known virulence for man," Arch. Virol. 54(1-2):19-28
	C39	Foote et al., 1995, "Kinetic and affinity limits on antibodies produced during immune response," Proc. Nat'l. Acad. Science USA 92:1254-1256
	C40	Foote et al., 1991, "Kinetic maturation of an immune response," Nature 352:530-532
	C41	Garvie et al., 1980, "Outbreak of respiratory syncytial virus infection in the elderly," Br. Med. J. 281(6250):1253-1254
	C42	Giraud et al., 1986, "Turkey rhinotracheitis in France: preliminary investigations on a ciliostatic virus," Vet. Rec. 119(24):606-607
	C43	Glaser et al., 1992, "Antibody engineering by codon-based mutagenesis in a filamentous phage vector system," J. Immunol. 149:3903-3913
	C44	Glezen et al., 1981, "Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level," J. Pediatr. 98(5):708-715
	C45	Greenspan et al., 1999, "Defining epitopes: It's not as easy as it seems," Nature Biotechnology 17:936-937
	C46	Groothuis et al., 1988, "Respiratory syncytial virus infection in children with bronchopulmonary dysplasia," Pediatrics 82(2):199-203
	C47	Groothuis et al., 1993, "Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children," The Respiratory Syncytial Virus Immune Globulin Study Group, N. Engl. J. Med. 329(21):1524-1530
	C48	Groves et al., 1987, "Production of an ovine monoclonal antibody to testosterone by an interspecies fusion," Hybridoma 6(1):71-76
	C49	Hacking et al., 2002, "Respiratory syncytial virus - viral biology and the host response," J. Infection 45:18-24
	C50	Hall et al., 1979, "Neonatal respiratory syncytial virus infection," N. Engl. J. Med. 300(8):393-396
	C51	Hall, 1993, "Respiratory Syncytial: What We Know Now," Contemp. Pediatrics 10:92-110
	C52	Hall et al., 1983, "Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study," N. Engl. J. Med. 308(24):1443-1447
	C53	Hall et al., 1985, "Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease," JAMA 254(21):3047-3051
	C54	Hall et al., 1975, "Nosocomial respiratory syncytial virus infections," N. Engl. J. Med. 293(26):1343-1346
	C55	Haynes et al., 2002, "Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection," J. Virol. 76(14):6873-6881
	C56	Heard et al., 1999, "Two neutralizing human RSV antibodies: cloning, expression, and characterization," Mol. Med. 5:35-45
	C57	Heckert et al., 1993, "Absence of antibodies to avian pneumovirus in Canadian poultry," Vet. Rec. 132(7):172
↓	C58	Hemming et al., 1985, "Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model," J. Infect. Dis. 152(5):1083-1087

MH	C59	Henderson et al., 1979, "Respiratory-syncytial-virus infections, reinfections and immunity: A prospective, longitudinal study in young children," N. Engl. J. Med. 300(10):530-534
	C60	Hertz et al., 1989, "Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: A clinical approach and review of the literature," Medicine (Baltimore) 68(5):269-281
	C61	Hoffmann et al., 2000, "A DNA transfection system for generation of influenza A virus from eight plasmids," Proc. Natl. Acad. Sci. USA 97(11):6108-6113
	C62	Howard et al., 1989, "Intracerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits," J. Neurosurg. 71(1):105-112
	C63	Huygelen et al., 1977, "Laboratory and clinical evaluation of new live influenza virus vaccines. Need for minimum requirements," Dev. Biol. Stand. 39:155-160
	C64	Inoue et al. 2003, "An improved method for recovering rabies virus from cloned cDNA," J. Virol. Methods. 107(2):229-236
	C65	Johnson et al., 1999, "A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZ19," J. Infect. Dis. 180(1):35-40
	C66	Johnson et al., 1987, "The G Glycoprotein of Human Respiratory Syncytial Viruses of Subgroups A and B: Extensive Sequence Divergence Between Antigenically Related Proteins," Proc. Natl. Acad. Sci. USA 84(16):5625-5629
	C67	Juhasz et al., 1994, "Extensive sequence variation in the attachment (G) protein gene of avian pneumovirus: evidence for two distinct subgroups," J. Gen. Virol. 75(Pt 11):2873-2880
	C68	Kapikian et al., 1969, "An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine," Am. J. Epidemiol. 89(4):405-421
	C69	Karlsson et al., 1997, "Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors," J. Immunol. Meth. 200:121-133
	C70	Kim et al., 1969, "Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine," Am. J. Epidemiol. 89(4):422-434
	C71	Knappik et al., 2000, "Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides," J. Mol. Biol. 296:57-86
	C72	Kreml et al., 2002, "Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positions," J. Virol. 76(23):11931-11942
	C73	Krystal et al., 1986, "Expression of the three influenza virus polymerase proteins in a single cell allows growth complementation of viral mutants," Proc. Natl. Acad. Sci. USA 83(8):2709-2713
	C74	Lam et al., 1997, "Microencapsulation of Recombinant Humanized Monoclonal Antibody for Local Delivery," Proc. Int'l. Symp. Control Rev. Bioact. Mater. 24:759-760
	C75	Lamprecht et al., 1976, "Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus," J. Infect. Dis. 134(3):211-217
	C76	Landry et al., "Evaluation of reconstituted lophilized palivizumab given intravenously at 15 and 30 mg/kg," Poster Session, Tuesday, Infect. Dis. 166A:969
	C77	Levy et al., 1985, "Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-release Diphosphonate," Science 228(4696):190-192
	C78	Ling et al., 1992, "Sequence analysis of the 22K, SH and G genes of turkey rhinotracheitis virus and their intergenic regions reveals a gene order different from that of other pneumoviruses," J. Gen. Virol. 73(Pt 7):1709-1715
	C79	Liu et al., 1987, "Expression of mouse::human immunoglobulin heavy-chain cDNA in lymphoid cells," Gene 54(1):33-40
	C80	LoBuglio et al., 1989, "Mouse/human chimeric monoclonal antibody in man: kinetics and immune response," Proc. Natl. Acad. Sci. USA 86(11):4220-4224
	C81	Lopez et al., 1998, "Antigenic structure of human respiratory syncytial virus fusion glycoprotein," J. Virol. 72(8):6922-6928
	C82	MacDonald et al., 1982, "Respiratory syncytial viral infection in infants with congenital heart disease," N. Engl. J. Med. 307(7):397-400
	C83	Marriott et al., 1999, "Reverse genetics of the Paramyxoviridae," Adv. Virus Res. 53:321-340
	C84	Marriott et al., 2001, "Fidelity of leader and trailer sequence usage by the respiratory syncytial virus and avian pneumovirus replication complexes," J. Virol. 75(14):6265-6272
	C85	Morell et al., eds., Clinical Use of Intravenous Immunoglobulins. Academic Press, London 1986, pp. 285-94
	C86	Morrison et al., 1985, "Transfectomas provide novel chimeric antibodies," Science 229(4719):1202-1207
↓	C87	Morrison et al., 1984, "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," Proc. Natl. Acad. Sci. USA 81(21):6851-6855


MH	C88	Murphy et al., 1994, "An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines," <i>Virus Res.</i> 32(1):13-36
	C89	Murphy et al., 1988, "Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses," <i>J. Virol.</i> 62(10):3907-3910
	C90	Murphy et al., 1991, "Effect of passive antibody on the immune response of cotton rats to purified F and G glycoproteins of respiratory syncytial virus (RSV)," <i>Vaccine</i> , 9(3):185-189
	C91	Myszka et al., 1999, "Survey of the 1998 optical biosensor literature," <i>J. Mol. Recog.</i> 12:390-408
	C92	Navas et al., 1992, "Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children," <i>Pediatric Investigators Collaborative Network on Infections in Canada, J. Pediatr.</i> 121(3):348-354
	C93	Naylor et al., 1998, "The ectodomains but not the transmembrane domains of the fusion proteins of subtypes A and B avian pneumovirus are conserved to a similar extent as those of human respiratory syncytial virus," <i>J. Gen. Virol.</i> 79(Pt 6):1393-1398
	C94	Neumann et al., 2002, "Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture," <i>J. Virol.</i> 76(1):406-410
	C95	Newman et al., 1992, "'Primitization' of recombinant antibodies for immunotherapy of human diseases: A Macaque/Hunab chimeric antibody against human CD4," 10:1455-1460
	C96	Ning et al., 1996, "Intratumoral Radioimmunotherapy of a Human Colon Cancer Xenograft Using a Sustained Release Gel," <i>Radiotherapy and Oncology</i> 39:179-189
	C97	O'Brien, 1985, "Swollen head syndrome in broiler breeders," <i>Vet. Rec.</i> 117(23):619-620
	C98	Ogra et al., "Respiratory syncytial virus infection and the immunocompromised host," <i>Pediatr. Infect. Dis. J.</i> 7(4):246-249
	C99	Palese et al., 1996, "Negative-strand RNA viruses: genetic engineering and applications," <i>Proc. Natl. Acad. Sci. USA</i> 93(21):11354-11358
	C100	Palivizumab et al., 1998, "A Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-Risk Infants," <i>The IMPact-RSV Study Group, Pediatrics</i> 102(3 Pt 1):531-537
	C101	Peeters et al., 1999, "Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence," <i>J. Virol.</i> 73(6):5001-5009
	C102	Peret et al., 2002, "Characterization of human metapneumoviruses isolated from patients in North America," <i>J. Infect. Dis.</i> 185(11):1660-1663
	C103	Poch et al., 1990, "Sequence comparison of five polymerases (L proteins) of unsegmented negative-strand RNA viruses: theoretical assignment of functional domains," <i>J. Gen. Virol.</i> 71(Pt 5):1153-1162
	C104	Poch et al., 1989, "Identification of four conserved motifs among the RNA-dependent polymerase encoding elements," <i>EMBO J.</i> 8(12):3867-3874
	C105	Pohl et al., 1992, "Respiratory syncytial virus infections in pediatric liver transplant recipients," <i>J. Infect. Dis.</i> 165(1):166-169
	C106	Press et al., 1970, "The amino acid sequences of the Fd fragments of two human gamma-1 heavy chains," <i>Biochem. J.</i> 117(4):641-660
	C107	Prince et al., 1996, "Treatment of parainfluenza virus type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid," <i>J. Infect. Dis.</i> 173:598-608
	C108	Prince et al., 1985, "Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat," <i>Virus Res.</i> 3(3):193-206
	C109	Prince et al., 1990, "Mechanism of antibody-mediated viral clearance in immunotherapy of respiratory syncytial virus infection of cotton rats," <i>J. Virol.</i> 64(6):3091-3092
	C110	Prince et al., 1983, "Mechanisms of immunity to respiratory syncytial virus in cotton rats," <i>Infect. Immun.</i> 42(1):81-87
	C111	Prince et al., 1985, "Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats," <i>J. Virol.</i> 55(3):517-520
	C112	Prince, 1975, Ph.D. diss., University of California, LA
	C113	Pringle, 1988, "Virus taxonomy - San Diego," <i>Arch. Virol.</i> 143(7):1449-1459
	C114	Pringle et al., 1999, "Virus taxonomy at the XIth International Congress of Virology, Sydney, Australia," <i>Arch. Virol.</i> 144(10):2065-2070
	C115	Raman et al., 1992, "Diffusion-limited rates for monoclonal antibody binding to cytochrome," <i>Biochem.</i> 31:10370-10379
	C116	Randhawa et al., 1997, "Rescue of synthetic minireplicons establishes the absence of the NS1 and NS2 genes



		from avian pneumovirus," J. Virol. 71(12):9849-9854
MH	C117	Roost et al., 1995, "Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity," PNAS USA 92:1257-1261
	C118	Rosok et al., 1995, "A combinatorial library strategy for the rapid humanization of anticarcinoma BR 96 Fab," JBC 271(27):22611-22618
	C119	Rudikoff et al., 1982, "Single amino acid substitution altering antigen-binding specificity," Proc. Natl. Acad. Sci. USA 79(6):1979-1983
	C120	Ruuskanen et al., "Respiratory syncytial virus," Curr. Probl. Pediatr. 23(2):50-79
	C121	Saez-Llorens et al., 1998, "Safety and Pharmacokinetics of an Intramuscular Humanized Monoclonal Antibody to Respiratory Syncytial Virus in Premature Infants and Infants with Bronchopulmonary Dysplasia," Pediatric Infect. Dis. J. 17(9):787-791
	C122	Saez-Llorens et al., 1997, "Phase I/II open label multi dose escalation trial of a humanized respiratory syncytial virus (RSV) monoclonal antibody (Medi-493) administered intramuscularly (IM) in high risk children," Abstracts in Non HIV virology, ICAAC Toronto
	C123	Sahagan et al., 1986, "A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen," J. Immunol. 137(3):1066-1074
	C124	Saudek et al., 1989, "A Preliminary Trial of the Pprogrammable Implantable Medication System for Insulin Delivery," N. Engl. J. Med. 321(9):574-579
	C125	Schier et al., 1996, "Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site," J. Mol. Biol. 263(4):551-567
	C126	Schnell et al., 1994, "Infectious rabies viruses from cloned cDNA," EMBO J. 13(18):4195-4203
	C127	Seal, 1998, "Matrix protein gene nucleotide and predicted amino acid sequence demonstrate that the first US avian pneumovirus isolate is distinct from European strains," Virus Res. 58(1-2):45-52
	C128	Sefton, 1987, "Implantable Pumps," CRC Crit. Rev. Biomed. Eng. 14(3):201-240
	C129	Senne et al., 1998, In: Proc. 47 <sup>th</sup> WPDC, CA, pp. 67-68
	C130	Skiadopoulos et al., 1998, "Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes," J. Virol. 72(3):1762-1768
	C131	Smith et al., 1991, "A Controlled Trial of Aerosolized Ribavirin in Infants Receiving Mechanical Ventilation for Severe Respiratory Syncytial Virus Infection," N. Engl. J. Med. 325(1):24-29
	C132	Song et al., 1995, "Antibody Mediated Lung Targeting of Long-Circulating Emulsions," PDA Journal of Pharmaceutical Science & Technology 50:372-397
	C133	Sorbera et al., 1998, "Palivizumab," Drugs of the Future 23:970-976
	C134	Sorbera et al., 1998, "Palivizumab," Drugs Data Report 20:702-703
	C135	Steplewski et al., 1988, "Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity," Proc. Natl. Acad. Sci. USA 85(13):4852-4856
	C136	Subramanian et al., "Safety, Tolerance and Pharmacokinetics of a Humanized Monoclonal Antibody to Respiratory Syncytial Virus in Premature Infants and Infants with Bronchopulmonary Dysplasia," Pediatric Infect. Dis. J. 17:110-115
	C137	Subramanian et al., 1997, "Randomized double blind placebo controlled dose escalation trial of a humanized respiratory syncytial virus monoclonal antibody in high risk infants," Poster session Infect. Dis. 130A:768
	C138	Sullender et al., 2000, "Respiratory syncytial virus genetic and antigenic diversity," Clin. Microbiol. Rev. 13(1):1-15
	C139	Sun et al., 1987, "Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A," Proc. Natl. Acad. Sci. USA 84(1):214-218
	C140	Takashi et al., 1984, "Angiomyolipoma of the kidney: report of three cases and a statistical study of 194 cases in Japan," Hinyokika Kiyo 30(1):65-75
	C141	Takeda et al., 1985, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," Nature 314(6010):452-454
	C142	Talwar et al., 1976, "Isoimmunization against human chorionic gonadotropin with conjugates of processed beta-subunit of the hormone and tetanus toxoid," Proc. Natl. Acad. Sci. USA 73(1):218-222
	C143	Tao et al., 1999, "A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge," Vaccine 17(9-10):1100-1108
↓	C144	Tao et al., 1998, "Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1," J. Virol. 72(4):2955-2961

MH	C145	Teng et al., 2000, "Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees," J. Virol. 74(19):9317-9321
	C146	van den Hoogen et al., 2001, "A newly discovered human pneumovirus isolated from young children with respiratory tract disease," Nat. Med. 7(6):719-724
	C147	van den Hoogen et al., 2002, "Analysis of the genomic sequence of a human metapneumovirus," Virology 295(1):119-132
	C148	van Wyke et al., 1985, "Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus," Virology 143(2):569-582
	C149	Volchkov et al., 2001, "Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity," Science 291(5510):1965-1969
	C150	Wald et al., 1988, "In re ribavirin: a case of premature adjudication?" J. Pediatr. 112(1):154-158
	C151	Walsh et al., 1987, "Immunization with Glycoprotein Subunits of Respiratory Syncytial Virus to Protect Cotton Rats Against Viral Infection," J. Infect. Dis. 155(6):1198-1204
	C152	Wright et al., 1982, "Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children," Infect. Immun. 37(1):397-400
	C153	Wu et al., 1998, "Stepwise in vitro affinity maturation of Vitaxin, an avb-specific humanized mAb," PNAS 95:6037-6042
	C154	Yu et al., 1992, "Cloning and sequencing of the matrix protein (M) gene of turkey rhinotracheitis virus reveal a gene order different from that of respiratory syncytial virus," Virology 186(2):426-434
↓	C155	Yu et al., 1992, "Sequence and in vitro expression of the M2 gene of turkey rhinotracheitis pneumovirus," J. Gen. Virol. 73(Pt 6):1355-1363

EXAMINER	/Michelle Horning/	DATE CONSIDERED	10/04/2006
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

Express Mail No.: **EV 452 775 206 US**

# **LIST OF REFERENCES CITED BY APPLICANT** (Use several sheets if necessary)

ATTY. DOCKET NO.

10271-072-999

APPLICATION NO.

10/628,088

APPLICANT

Young et al.

FILING DATE

July 25, 2003

GROUP

1641

## **U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
MH	A41	6,605,283	8/12/03	Seal et al.			
MH	A42	6,168,786	1/2/01	Klein et al.			
	A43						
	A44						
	A45						
	A46						
	A47						
	A48						
	A49						
	A50						
	A51						

## **FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01							
	B02							
	B03							
	B04							
	B05							
	B06							

## **OTHER REFERENCES** (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	
	C02	
	C03	

EXAMINER /Michelle Horning/

DATE CONSIDERED

10/04/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.